transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2018-5-5-37-45transmed-441Research ArticleОНКОЛОГИЧЕСКИЕ ЗАБОЛЕВАНИЯCANCERСОВРЕМЕННЫЕ ТЕХНОЛОГИИ ЯДЕРНОЙ МЕДИЦИНЫ В ДИАГНОСТИКЕ ОПУХОЛЕЙ ГОЛОВНОГО МОЗГА (ОБЗОР ЛИТЕРАТУРЫ)MODERN TECHNOLOGIES OF NUCLEAR MEDICINE IN DIAGNOSIS OF BRAIN TUMORS (LITERATURE REVIEW)КостениковН. А.KostenikovN. A.

д.м.н., главный научный сотрудник, заведующий лабораторией радиофармацевтических технологий отдела фундаментальных исследований

nkostenikov@yandex.ruПоздняковА. В.PozdnyakovA. V.

д.м.н., профессор, заведующий отделением лучевой диагностики клиники, заведующий кафедрой медицинской биофизики ФГБОУ ВО «СПБГПМУ» Минздрава России; главный научный сотрудник, заведующий лабораторией нейровизуализации ФГБУ «РНЦРХТ им. ак. А. М. Гранова»

poozdnyakovalex@yandex.ruСтанжевскийА. А.StanzhevskiyA. A.

д.м.н., заместитель директора по научной работе ФГБУ «РНЦРХТ им. ак. А. М. Гранова» Минздрава России, профессор курса радиологии кафедры лучевой диагностики и медицинской визуализации Института медицинского образования ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России

stanzhevsky@gmail.comМихетькоА. А.MihetkoA. A.

младший научный сотрудник лаборатории радиофармацевтических технологий отдела фундаментальных исследований

m.rogachev@mail.ruИлющенкоЮ. Р.IliuschenkoYu. R.

радиолог

Федеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А. М. Гранова» Министерства здравоохранения Российской Федерации, Санкт-ПетербургРоссияFederal State Budgetary Institution “Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov”, Ministry of Health of the Russian Federation, Saint PetersburgRussian FederationФедеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А. М. Гранова» Министерства здравоохранения Российской Федерации, Санкт-Петербург; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации, Санкт-ПетербургРоссияFederal State Budgetary Institution “Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov”, Ministry of Health of the Russian Federation, Saint Petersburg; Federal State Budgetary Educational Institution of Higher Education “Saint Petersburg State Pediatric Medical University” of the Ministry of Health of the Russian Federation, Saint PetersburgRussian FederationФедеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А. М. Гранова» Министерства здравоохранения Российской Федерации, Санкт-Петербург; Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации, Санкт-ПетербургРоссияFederal State Budgetary Institution “Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov”, Ministry of Health of the Russian Federation, Saint Petersburg; Almazov National Medical Research Center, Saint PetersburRussian FederationФедеральное государственное бюджетное учреждение «Российский научный центр радиологии и хирургических технологий имени академика А. М. Гранова» Министерства здравоохранения Российской Федерации, Санкт-ПетербургРоссияFederal State Budgetary Institution “Russian Research Center of Radiology and Surgical Technologies named after Academician A. M. Granov”, Ministry of Health of the Russian Federation, Saint PetersburgRussian Federation201803122018553745Copyright © Костеников Н.А., Поздняков А.В., Станжевский А.А., Михетько А.А., Илющенко Ю.Р., 20182018Костеников Н.А., Поздняков А.В., Станжевский А.А., Михетько А.А., Илющенко Ю.Р.Kostenikov N.A., Pozdnyakov A.V., Stanzhevskiy A.A., Mihetko A.A., Iliuschenko Y.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/441

В обзоре представлен анализ литературы, посвященной диагностике опухолей головного мозга и изучению их структурных и биологических особенностей на базе использования современных технологий ядерной медицины: однофотонной эмиссионной компьютерной томографии (ОФЭКТ) и позитронно-эмиссионной томографии, совмещенной с компьютерной томографией (ПЭТ-КТ) с различными РФП (радиофармацевтическими препаратами), в первую очередь, мечеными аминокислотами, такими как 11С-L-метионин и 18F-фтор-этилтирозин. Показано, что с помощью данных, полученных этими методами, особенно ПЭТ-КТ с меченными аминокислотами, могут быть неинвазивным путем изучены важнейшие биохимические процессы, лежащие в основе онкогенеза. Эти данные имеют решающее значение для раннего выявления опухолевого поражения, определения степени злокачественности опухоли, стадирования патологического процесса, обоснования лечебной тактики, персонализации лечения, оценки эффективности терапии в ранние сроки и прогнозирования исхода заболевания.

 

The review presents an analysis of the literature on the diagnosis of brain tumors and the study of their structural and biological features based on application of nuclear imaging: single photon emission computed tomography (SPECT) and positron emission tomography (PET) with different radiopharmaceuticals (RPHs), especially amino acids (11C-L-methionine and 18F-FET). It is shown PET-CT and SPECT allow to noninvasively study the most important biochemical processes underlying the oncogenesis. The obtained data can be crucial for an early detection of tumor lesion, staging the pathological process, personalization of treatment, evaluation of the efficiency of therapy and prognosis of the oncologic disease outcome.

опухоли головного мозгалучевые методы диагностикимолекулярная визуализациярадиофармпрепаратыпозитронно-эмиссионная томографияоднофотонная эмиссионная компьютерная томографияbrain tumorsradiation diagnostic methodsmolecular imagingradiopharmaceuticalspositron emission tomographysingle-photon emission computed tomographyReferencesRasmussen BK, Hansen S, Laursen RJ et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol. 2017;135(3):571-579.Rasmussen B.K, Hansen S., Laursen RJ, et al. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. J Neurooncol. 2017 Dec;135(3):571-579. doi: 10.1007/s11060-017-2607-5. Epub 2017 Aug 31.Tabouret E, Bauchet L, Carpentier AF. Brain metastases epidemiology and biology. Bull Cancer. 2013;100(1):57-62.Tabouret E1, Bauchet L, Carpentier AF. Brain metastases epidemiology and biology. Bull Cancer. 2013 Jan 1;100(1):57-62. doi: 10.1684/bdc.2012.1681.de Robles P, Fiest KM, Frolkis AD et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015;17(6):776-83.de Robles P, Fiest KM, Frolkis AD, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015 Jun;17(6):776-83. doi: 10.1093/neuonc/nou283. Epub 2014 Oct 13.Inubushi M, Tatsumi M, Yamamoto Y et al. European research trends in nuclear medicine. Ann Nucl Med. 2018;32(9):579-582.Inubushi M, Tatsumi M, Yamamoto Y, et al. European research trends in nuclear medicine. Ann Nucl Med. 2018 Nov;32(9):579-582. doi: 10.1007/s12149-018-1303-7. Epub 2018 Sep 21. ReviewKarpuz M, Silindir-Gunay M, Ozer AY. Current and Future Approaches for Effective Cancer Imaging and Treatment. Cancer Biother Radiopharm. 2018;33(2):39-51.Granov А., Tiutin L., Schwartz T., editors Positron Emission Tomography: «Springer-Verlag», Heideberg, Berlin; 2013.Mabray MC, Barajas RF Jr, Cha S. Modern brain tumor imaging. Brain Tumor Res Treat. 2015;3(1):8-23.Mabray MC, Barajas RF Jr, Cha S Modern brain tumor imaging. Brain Tumor Res Treat. 2015 Apr;3(1):8-23. doi: 10.14791/btrt.2015.3.1.8. Epub 2015 Apr 29.Livieratos L. Technical pitfalls and limitations of SPECT/CT. Semin Nucl Med. 2015;45(6):530-40.Livieratos L. Technical pitfalls and limitations of SPECT/CT Semin Nucl Med. 2015 Nov;45(6):530-40. doi: 10.1053/j.semnuclmed.2015.06.002.Le Jeune FP, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol. 2006;77(2):177-83.Murari SB, Manthri RG, Gadepalli T, et al. Comparison of 99M Technetium Sestamibi Brain Single Photon Emission Computed Tomography (SPECT) with Computed Tomography (CT) & Magnetic Resonance Imaging (MRI) in Differentiating Tumor Recurrence From Radiation Necrosis in Post Therapeutic Gliomas. IJSR 2016 Sep.; 5 (9): 975-979.Cecchin D, Chondrogiannis S, Della Puppa A et al. Presurgical 99mTc-sestamibi brain SPET/CT versus SPET: a comparison with MRI and histological data in 33 patients with brain tumours. Nucl Med Commun. 2009;30(9):660-8.Cecchin D1, Chondrogiannis S, Della Puppa A, et al. Presurgical 99mTc-sestamibi brain SPET/CT versus SPET: a comparison with MRI and histological data in 33 patients with brain tumours. Nucl Med Commun. 2009 Sep;30(9):660-8. doi: 10.1097/MNM.0b013e32832ea9b7 10.Shibata Y, Yamamoto T, Takano S et al. Direct comparison of thallium-201 and technetium-99m MIBI SPECT of a glioma by receiver operating characteristic analysis. J Clin Neurosci. 2009;16(2):264-9.Shibata Y1, Yamamoto T, Takano S, et al. Direct comparison of thallium-201 and technetium-99m MIBI SPECT of a glioma by receiver operating characteristic analysis. J Clin Neurosci. 2009 Feb;16(2):264-9. doi: 10.1016/j.jocn.2008.04.010. Epub 2008 Dec 11.Woesler B, Kuwert T, Morgenroth C et al. Noninvasive grading of primary brain tumours: results of a comparative study between SPET with 123I-α-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med. 1997;24(4):428-34.Woesler B, Kuwert T, Morgenroth C, et al. Non-invasive grading of primary brain tumours: Results of a comparative study between SPET with123I-α-methyl tyrosine and PET with18F-deoxyglucose Eur J Nucl Med.-1997.-Vol. 24, N 4.-P. 428-34.Kuczer D, Feussner A, Wurm R et al. 123I-IMT SPECT for evaluation of the response to radiation therapy in high grade gliomas: a feasibility study. Br J Radiol. 2007;80(952):274-8.Kuczer D, Feussner A, Wurm R, et al. 123I-IMT SPECT for evaluation of the response to radiation therapy in high-grade gliomas: a feasibility study. Br J Radiol. 2007 Apr;80(952):274-8. Epub 2006 Nov 22.Vander Borght T, Asenbaum S, Bartenstein P et al. EANM Procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33(11):1374-80.Vander Borght T, Asenbaum S, Bartenstein P, et al. EANM Procedure Guidelines for Brain Tumour Imaging using Labelled Amino Acid Analogues // Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1374-80.Grosu AL, Feldmann H, Dick S et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys. 2002;54(3):842-54.Grosu AL, Feldmann H, Dick S, et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):842-54.Samnick S, Hellwig D, Bader JB et al. Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-L-phenylalanine for routine brain tumour imaging. Nucl Med Commun. 2002;23(2):121-30.Samnick S1, Hellwig D, Bader JB, et al. Initial evaluation of the feasibility of single photon emission tomography with p-[123I]iodo-L-phenylalanine for routine brain tumour imaging. Nucl Med Commun. 2002 Feb;23(2):121-30.Amin A, Moustafa H, Ahmed E et al. Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1 H-MRS): initial results. J Neurooncol. 2012;106(3):579-87.Amin A, Moustafa H, Ahmed E, El-Toukhy M. Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1 H-MRS): initial results. J Neurooncol. 2012 Feb;106(3):579-87. doi: 10.1007/s11060-011-0694-2. Epub 2011 Sep 13.Sehweil AM, McKillop JH, Milroy R et al. Mechanism of 201Tl uptake in tumours. Eur J Nucl Med. 1989;15(7):376-9.Sehweil AM, McKillop JH, Milroy R et al.. Mechanism of 201Tl uptake in tumours. Eur J Nucl Med. 1989;15(7):376-9.Sun D, Liu Q, Liu W et al. Clinical application of 201Tl SPECT imaging of brain tumors. J Nucl Med. 2000;41(1):5-10.Sun D1, Liu Q, Liu W, Hu W Clinical application of 201Tl SPECT imaging of brain tumors. J Nucl Med. 2000 Jan;41(1):5-10.Matsunaga S, Shuto T, Takase H et al. Semiquantitative analysis using thallium-201 SPECT for differential diagnosis between tumor recurrence and radiation necrosis after gamma knife surgery for malignant brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(1):47-52.Matsunaga S1, Shuto T, Takase H, et al. Semiquantitative analysis using thallium-201 SPECT for differential diagnosis between tumor recurrence and radiation necrosis after gamma knife surgery for malignant brain tumors. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):47-52. doi: 10.1016/j.ijrobp.2012.03.008. Epub 2012 Apr 27.Nadeem Q, Khan I, Javed M, et al. Synthesis, characterization and bioevaluation of technetium-99m labeled N-(2-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose as a tumor imaging agent. Pak J Pharm Sci. 2013;26(2):353-357.Skuridin VS, Stasyuk ES., Ilyina EA, et al. Obtaining Technetium-99m-Labeled Glucose Derivatives. Advanced Materials Research 2015;1084: 567-571.Ono Y, Chernov MF, Muragaki Y et al. Imaging of Intracranial Gliomas. Prog Neurol Surg. 2018;30:12-62.Ono Y, Chernov MF, Muragaki Y, et al. Imaging of Intracranial Gliomas. Prog Neurol Surg. 2018;30:12-62. doi: 10.1159/000464376. Epub 2017 Dec 14. Review.Jung JH, Ahn BC. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Res Treat. 2018;6(2):47-53.Vallabhajosula S. Molecular Imaging. Radiopharmaceuticals for PET and SPECT. // Springer, 2012. – NY, USA. – 370 p.Larsson EM, Wikström J. Overview of neuroradiology. Handb Clin Neurol. 2017;145:579-599.Larsson EM, Wikström J. Overview of neuroradiology. Handb Clin Neurol. 2017;145:579-599. doi: 10.1016/B978-0-12-802395-2.00037-7. Review.Herzog H, Van Den Hoff J. Combined PET/MR systems: an overview and comparison of currently available options. Q J Nucl Med Mol Imaging. 2012;56(3):247-67.Herzog H, Van Den Hoff J. Combined PET/MR systems: an overview and comparison of currently available options Q J Nucl Med Mol Imaging. 2012 Jun;56(3):247-67.Palanichamy K, Chakravarti A. Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas. Front Oncol. 2017;7:257.Palanichamy K, Chakravarti A. Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas. Front Oncol. 2017 Nov 1;7:257. doi: 10.3389/fonc.2017.0025726.Dandois V, Rommel D, Renard L et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol. 2010;37(2):89-97.Dandois V1, Rommel D, Renard L, et al.. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice. J Neuroradiol. 2010 May;37(2):89-97. doi: 10.1016/j.neurad.2009.04.005. Epub 2009 Jun 30.Sharma S. PET Radiopharmaceuticals for Personalized Medicine. Curr Drug Targets. 2016;17(16):1894-1907.Sharma S. PET Radiopharmaceuticals for Personalized Medicine. Curr Drug Targets. 2016;17(16):1894-1907. Review.Ullrich RT, Kracht L, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50(12):1962-8.Ullrich RT1, Kracht L, Brunn A, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma J Nucl Med. 2009 Dec;50(12):1962-8. doi: 10.2967/jnumed.109.065904. Epub 2009 Nov 12. 29. 29. Grosu AL1, Weber WA, Riedel E,, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74.Grosu AL, Weber WA, Riedel E et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(1):64-74.Jansen NL, Suchorska B, Wenter V, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014 Feb;55(2):198-203. doi: 10.2967/jnumed.113.122333. Epub 2013 Dec 30.Jansen NL, Suchorska B, Wenter V et al. Dynamic 18F-FET PET in newly diagnosed astrocytic lowgrade glioma identifies high-risk patients. J Nucl Med. 2014;55(2):198-203.Jansen NL, Suchorska B, Wenter V, et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2015 Jan;56(1):9-15. doi: 10.2967/jnumed.114.144675.Jansen NL, Suchorska B, Wenter V et al. Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma. J Nucl Med. 2015;56(1):9-15.Albert NL, Winkelmann I, Suchorska B et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1105-14.Albert NL, Winkelmann I, Suchorska B et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol Imaging. 2016;43(6):1105-14.Langen KJ1, Hamacher K, Weckesser M, et al. O-(2-[18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications Nucl Med Biol. 2006 Apr;33(3):287-94.Langen KJ, Hamacher K, Weckesser M et al. O-(2-[18F] fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol. 2006;33(3):287-94.Dunet V1, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012 Feb;53(2):207-14. doi: 10.2967/jnumed.111.096859.Dunet V, Rossier C, Buck A et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012;53(2):207-14.Pöpperl G1, Kreth FW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1933-42. Epub 2007 Sep 1.Pöpperl G, Kreth FW, Mehrkens JH et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34(12):1933-42.Harat M, Małkowski B, Makarewicz R. Pre-irradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study. Radiother Oncol. 2016 Aug;120(2):241-7. doi: 10.1016/j.radonc.2016.06.004. Epub 2016 Jul 1.Harat M, Małkowski B, Makarewicz R. Preirradiation tumour volumes defined by MRI and dual time-point FET-PET for the prediction of glioblastoma multiforme recurrence: A prospective study. Radiother Oncol. 2016;120(2):241-7.Galldiks N1, Langen KJ, Holy R., et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012 Jul;53(7):1048-57. doi: 10.2967/jnumed.111.098590. Epub 2012 May 29..Galldiks N, Langen KJ, Holy R et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012;53(7):1048-57.Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014 Jun;12(3):148-57. doi: 10.1016/j.surge.2013.12.001. Epub 2014 Mar 11. Review.Demetriades AK, Almeida AC, Bhangoo RS et al. Applications of positron emission tomography in neurooncology: a clinical approach. Surgeon. 2014;12(3):148-57.Fueger BJ1, Czernin J, Cloughesy T, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas J Nucl Med. 2010 Oct;51(10):1532-8. doi: 10.2967/jnumed.110.078592. Epub 2010 Sep 16.Fueger BJ, Czernin J, Cloughesy T et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010;51(10):1532-8.Walter F1, Cloughesy T, Walter MA, et al. Impact of 3, 4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective //Journal of nuclear medicine. J Nucl Med. 2012 Mar;53(3):393-8. doi: 10.2967/jnumed.111.095711. Epub 2012 Feb 9.Walter F, Cloughesy T, Walter MA et al. Impact of 3, 4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/ CT on managing patients with brain tumors: the referring physician’s perspective. J Nucl Med. 2012;53(3):393-8.Chen W1, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006 Jun;47(6):904-11.Chen W, Silverman DH, Delaloye S et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47(6):904-11.Wardak M1, Schiepers C, Cloughesy TF, et al. 18 F-FLT and 18 F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1199-209. doi: 10.1007/s00259-013-2678-2. Epub 2014 Mar 7.Wardak M, Schiepers C, Cloughesy TF et al. 18 F-FLT and 18 F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014;41(6):1199-1209.Yamamoto Y1, Ono Y, Aga F, et al. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med. 2012 Dec;53(12):1911-5. doi: 10.2967/jnumed.112.104729. Epub 2012 Oct 18.Yamamoto Y, Ono Y, Aga F et al. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med. 2012;53(12):1911-5.Jonson SD, Welch MJ. Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids Nucl Med Biol. 2002 Feb;29(2):211-6.Jonson SD, Welch MJ. Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids. Nucl Med Biol. 2002;29(2):211-6.Lam WW, Ng DC, Wong WY, et al. Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors—early experience. Clin Neurol Neurosurg. 2011 Feb;113(2):156-61. doi: 10.1016/j.clineuro.2010.09.012. Epub 2010 Oct 30.Lam WW, Ng DC, Wong WY et al. Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors—early experience. Clin Neurol Neurosurg. 2011;113(2):156-61.Giovannini E, Lazzeri P, Milano A, et al. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015;21(1):121-7. Review.Giovannini E, Lazzeri P, Milano A et al. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015;21(1):121-7.Giovannini E, Lazzeri P, Milano A et al. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015;21(1):121-7.

The authors declare that there are no conflicts of interest present.